3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow CG 400549: new trials by email Literature Review of CG 400549 trials Research Report on CG 400549
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus CG400549 - Skin Infection | Phase 2 | Completed | CrystalGenomics, Inc. | 20 | 2012-06-01 | 2022-09-10 |
| Multiple Ascending Doses Study of CG400549 CG400549 640mg, CG400549 320 mg, CG400549 640 mg - Healthy | Phase 1 | Completed | CrystalGenomics, Inc. | 32 | 2010-05-01 | 2013-05-07 |
| CG400549 Single Ascending Dose Study CG400549/placebo, CG400549 - Healthy | Phase 1 | Completed | CrystalGenomics, Inc. | 18 | 2009-10-01 | 2022-05-20 |
Cellulitis (1)
Netherlands (2) · United States (1)
Seonggu Ro, PhD (2) · Jeffrey S. Overcash, MD (1)